StockNews.AI
UHS
StockNews.AI
174 days

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND 2025 OPERATING RESULTS FORECAST

1. UHS reported Q4 2024 net income of $332.4 million, up 53.8% YoY. 2. Net revenues for Q4 2024 soared 11.1% to $4.114 billion. 3. Adjusted EBITDA increased to $614.6 million, a significant rise YoY. 4. 2025 forecast predicts revenues of $17.020 billion to $17.364 billion. 5. UHS repurchased 2.98 million shares in 2024 at $201 average price.

86m saved
Insight
Article

FAQ

Why Very Bullish?

Strong financial performance and revenue growth typically boost investor confidence. For example, UHS's revenue growth aligns with positive market trends in healthcare stocks.

How important is it?

Financial performance coupled with stock buyback programs often lead to stock price appreciation and is crucial for investor sentiment.

Why Long Term?

Sustained growth in revenues and earnings support a positive long-term trend, similar to previous years' healthcare performance.

Related Companies

Consolidated Results of Operations, As Reported and As Adjusted  – Three-month periods ended December 31, 2024 and 2023: , /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $332.4 million, or $4.96 per diluted share, during the fourth quarter of 2024, as compared to $216.4 million, or $3.16 per diluted share, during the fourth quarter of 2023. Net revenues increased by 11.1% to $4.114 billion during the fourth quarter of 2024, as compared to $3.704 billion during the fourth quarter of 2023. As reflected on the Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule"), our adjusted net income attributable to UHS during the fourth quarter of 2024 was $329.9 million, or $4.92 per diluted share, as compared to $214.9 million, or $3.13 per diluted share, during the fourth quarter of 2023.  As reflected on the Supplemental Schedule, included in our reported results during the fourth quarter of 2024 were: (i) an unrealized after-tax gain of $2.1 million, or $.03 per diluted share ($2.7 million pre-tax), resulting from an increase in the market value of certain equity securities (included in "Other (income) expense, net"), and; (ii) a favorable net after-tax impact of $407,000, or $.01 per diluted share, resulting from the net tax benefit recorded pursuant to "ASU 2016-09", Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting.     Included in our reported and adjusted net income attributable to UHS during the fourth quarter of 2023, were net incremental reimbursements (net of related provider taxes) of approximately $17.8 million, or $.20 per diluted share, recorded in connection with the Mississippi Hospital Access Program covering the period of July 1, 2023, through December 31, 2023.  In addition, as reflected on the Supplemental Schedule, included in our reported results during the fourth quarter of 2023, was an unrealized after-tax gain of $1.5 million, or $.03 per diluted share ($1.9 million pre-tax), resulting from an increase in the market value of certain equity securities. As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization ("EBITDA net of NCI", NCI is net income attributable to noncontrolling interests), was $620.2 million during the fourth quarter of 2024, as compared to $476.9 million during the fourth quarter of 2023. Our adjusted earnings before interest, taxes, depreciation & amortization ("Adjusted EBITDA net of NCI"), which excludes the impact of other (income) expense, net, was $614.6 million during the fourth quarter of 2024, as compared to $473.4 million during the fourth quarter of 2023. Consolidated Results of Operations, As Reported and As Adjusted  – Twelve-month periods ended December 31, 2024 and 2023: Reported net income attributable to UHS was $1.142 billion, or $16.82 per diluted share, during the full year 2024, as compared to $717.8 million, or $10.23 per diluted share, during 2023. Net revenues increased by 10.8% to $15.828 billion during the full year of 2024, as compared to $14.282 billion during 2023. As reflected on the Supplemental Schedule, our adjusted net income attributable to UHS during the twelve-month period ended December 31, 2024, was $1.128 billion, or $16.61 per diluted share, as compared to $739.4 million, or $10.54 per diluted share, during the twelve-month period ended December 31, 2023.  As reflected on the Supplemental Schedule, included in our reported results during the full year of 2024 were: (i) an unrealized after-tax loss of $2.0 million, or $.03 per diluted share ($2.6 million pre-tax), resulting from a decrease in the market value of certain equity securities (included in "Other (income) expense, net"), and; (ii) a favorable net after-tax impact of $15.9 million, or $.24 per diluted share, resulting from the above-mentioned net tax benefit recorded in connection with ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m).      As reflected on the Supplemental Schedule, included in our reported results during 2023 was an unrealized after-tax loss of $21.6 million, or $.31 per diluted share ($28.2 million pre-tax) resulting from a decrease in the market value of certain equity securities.  As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization ("EBITDA net of NCI"), was $2.248 billion during the full year of 2024, as compared to $1.714 billion during the full year of 2023. Our adjusted earnings before interest, taxes, depreciation & amortization ("Adjusted EBITDA net of NCI"), which excludes the impact of other (income) expense, net, was $2.246 billion during the full year of 2024, as compared to $1.742 billion during the full year of 2023. Acute Care Services – Three and twelve-month periods ended December 31, 2024 and 2023: During the fourth quarter of 2024, at our acute care hospitals owned during both periods ("same facility basis"), adjusted admissions (adjusted for outpatient activity) increased by 2.2% while adjusted patient days increased by 0.1%, as compared to the fourth quarter of 2023. At these facilities, during the fourth quarter of 2024, net revenue per adjusted admission increased by 5.3% while net revenue per adjusted patient day increased by 7.5%, as compared to the fourth quarter of 2023. Net revenues generated from our acute care services, on a same facility basis, increased by 8.7% during the fourth quarter of 2024, as compared to the fourth quarter of 2023.  During the twelve-month period ended December 31, 2024, at our acute care hospitals on a same facility basis, adjusted admissions increased by 2.9% while adjusted patient days increased by 1.8%, as compared to the year ended December 31, 2023. At these facilities, during the full year of 2024, net revenue per adjusted admission increased by 5.1% while net revenue per adjusted patient day increased by 6.3%, as compared to 2023. Net revenues generated from our acute care services, on a same facility basis, increased by 8.5% during the full year of 2024, as compared to 2023. Behavioral Health Care Services – Three and twelve-month periods ended December 31, 2024 and 2023: During the fourth quarter of 2024, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 2.0% while adjusted patient days increased by 1.6%, as compared to the fourth quarter of 2023. At these facilities, during the fourth quarter of 2024, net revenue per adjusted admission increased by 8.7% and net revenue per adjusted patient day increased by 9.1%, as compared to the fourth quarter of 2023. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 11.1% during the fourth quarter of 2024, as compared to the fourth quarter of 2023. During the twelve-month period ended December 31, 2024, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 0.7% while adjusted patient days increased by 1.7%, as compared to the comparable period of 2023. At these facilities, during the full year of 2024, net revenue per adjusted admission increased by 9.8% and net revenue per adjusted patient day increased by 8.8%, as compared to 2023. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 10.7% during 2024, as compared to 2023. Net Cash Provided by Operating Activities and Liquidity: Net Cash Provided by Operating Activities: During the twelve-month period ended December 31, 2024, our net cash provided by operating activities was $2.067 billion as compared to $1.268 billion during the full year of 2023. The $799 million net increase in our net cash provided by operating activities consisted of: (i) a favorable change of $472 million resulting from an increase in net income plus/minus depreciation and amortization expense, stock-based compensation expense, gains on sales of assets and businesses and costs related to the extinguishment of debt; (ii) a favorable change of $250 million in accounts receivable due, in part, to a decrease in our days sales outstanding to 50 days at December 31, 2024, as compared to 57 days at December 31, 2023; (iii) a favorable change of $94 million in other working capital accounts due primarily to the timing of disbursements for certain accrued liabilities; (iv) an unfavorable change of $61 million in other assets and deferred charges; (v) a favorable change of $56 million in accrued and deferred income taxes, and; (vi) $12 million of other combined net unfavorable changes.      Liquidity: As of December 31, 2024, we had $1.17 billion of aggregate available borrowing capacity pursuant to our $1.3 billion revolving credit facility, net of outstanding borrowings and letters of credit.        Stock Repurchase Program: In connection with our stock repurchase program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions.  Pursuant to this program, during the fourth quarter of 2024, we have repurchased approximately 1.25 million shares at an aggregate cost of approximately $249.6 million (average price of approximately $199 per share). During the full year of 2024, we have repurchased approximately 2.98 million shares at an aggregate cost of approximately $598.5 million (average price of approximately $201 per share). As of December 31, 2024, we had an aggregate available repurchase authorization of approximately $824.4 million pursuant to our stock repurchase program. 2025 Operating Results Forecast: Reflected below is our 2025 forecasted range for consolidated net revenues, earnings before interest, taxes, depreciation & amortization, and the impacts of other income/expense and net income attributable to noncontrolling interests ("Adjusted EBITDA net of NCI"), net income attributable to UHS per diluted share ("EPS-diluted") and capital expenditures.  Our 2025 forecasted range of net income attributable to UHS, and EPS-diluted, exclude certain items as described below because we do not believe we can forecast those items with sufficient accuracy. Adjusted EBITDA net of NCI, is a non-GAAP financial measure and should not be considered a measure of financial performance under GAAP. We believe Adjusted EBITDA net of NCI is helpful to our investors as a measure of our operating performance. Please see the Supplemental Non-GAAP Disclosures - 2025 Operating Results Forecast schedule as included herein for additional information and a reconciliation of our 2025 forecasted range of net income attributable to UHS to our 2025 forecasted range of Adjusted EBITDA net of NCI.  For the Year Ended December 31, 2025 Low High Net revenues $17.020 billion $17.364 billion Adjusted EBITDA net of NCI $2.357 billion $2.484 billion  EPS-diluted $18.45 per share $19.95 per share Capital expenditures $850 million $1.000 billion Our 2025 operating results forecast contains a number of assumptions including, but not limited to, the following: The 2025 forecasted amounts exclude the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as changes in the market value of shares of certain equity securities, the impact of ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m), and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary acquisitions, divestitures, joint ventures or other strategic transactions, other amounts that may be reflected in the current or prior year financial statements that relate to prior periods, and the impact of share repurchases that differ from our forecasted assumptions. It is also subject to certain conditions including those as set forth below in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures. Our net revenues are estimated to be approximately $17.020 billion to $17.364 billion representing an increase of 7.5% to 9.7% over our 2024 net revenues of $15.828 billion. Our Adjusted EBITDA net of NCI is estimated to be approximately $2.357 billion to $2.484 billion representing an increase of 4.9% to 10.6% over our 2024 Adjusted EBITDA net of NCI of $2.246 billion. Our EPS-diluted range is estimated to be $18.45 per diluted share to $19.95 per diluted share, representing an increase of 11.1% to 20.1% over our adjusted net income attributable to UHS of $16.61 per diluted share for the year ended December 31, 2024, as calculated on the attached Supplemental Schedule. Conference call information: We will hold a conference call for investors and analysts at 10:00 a.m. eastern time on February 27, 2025. A live webcast of the call will be available on our website at www.uhs.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call. General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures: One of the nation's largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. (the "Company") has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2024 were $15.828 billion. UHS ranked #299 on the Fortune 500; and #399 on Forbes' list of America's Largest Public Companies. In 2025, UHS was again recognized as one of the World's Most Admired Companies by Fortune.   Our operating philosophy is as effective today as it was upon the Company's founding in 1979, enabling us to provide compassionate care to our patients and their loved ones.  Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve. Headquartered in King of Prussia, PA, UHS has approximately 99,000 employees and, through its subsidiaries, operates 28 inpatient acute care hospitals, 331 inpatient behavioral health facilities, 60 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 states, Washington, D.C., the United Kingdom and Puerto Rico. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT).  For additional information visit www.uhs.com.             This press release contains forward-looking statements based on current management expectations.  Numerous factors, including those disclosed herein, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A-Risk Factors, and Item 7-Forward-Looking Statements and Risk Factors, in our Form 10-K for the year ended December 31, 2024), may cause the results to differ materially from those anticipated in the forward-looking statements.  These statements are subject to risks and uncertainties and therefore actual results may differ materially.  Readers should not place undue reliance on such forward-looking statements which reflect management's view only as of the date hereof.  We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  Many of the factors that could affect our future results are beyond our control or ability to predict, including, but not limited to:   A significant portion of our revenues are derived from federal and state government programs including the Medicare and Medicaid programs. Payments from these programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions. Changes to these programs, if adopted, could materially affect program payments which could materially impact our results of operations. In addition, we receive substantial reimbursement from multiple states in connection with various supplemental Medicaid payment programs. Failure to renew these programs beyond their scheduled termination dates, failure of the public hospitals to provide the necessary Inter-Governmental Transfers for the states' share of the Medicaid disproportionate share hospital programs, failure of our hospitals that currently receive supplemental Medicaid revenues to qualify for future funds under these programs, the adoption of certain proposed reductions of federal funding for Medicaid, or reductions in other reimbursements, could cause our actual results of operations for the year ended December 31, 2025 to differ materially from our 2025 operating results forecast. The increase in interest rates during the past few years has increased our interest expense significantly thereby reducing our free cash flow. As such, although interest rates have moderated more recently, the effects of increased borrowing rates have adversely impacted our results of operations, financial condition and cash flows. We cannot predict future changes to interest rates, however, significant increases in our borrowing rates could have a material unfavorable impact on our future results of operations and our ability to access the capital markets on favorable terms; The outcome of known and unknown litigation, liabilities and other claims asserted against us and/or our subsidiaries, including, but not limited to, the matters related to Cumberland Hospital for Children and Adolescents, located in New Kent, Virginia, as previously disclosed on Form 8-K on September 30, 2024, Form 10-Q for the quarterly period ended September 30, 2024 and Form 10-K for the year ended December 31, 2024; and the matter related to the Pavilion Behavioral Health System, located in Champaign, Illinois, as previously disclosed on Forms 8-K on April 1, 2024, September 30, 2024 and October 11, 2024, Forms 10-Q for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024 and Form 10-K for the year ended December 31, 2024. Although we can make no assurances regarding the ultimate outcome of these matters, or what damages will ultimately be awarded, the final resolution of these matters could have a material adverse effect on the Company. We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures ("GAAP" is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities, the impact of ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m), and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary acquisitions, divestitures, joint ventures or other strategic transactions, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2024. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance. Universal Health Services, Inc. Consolidated Statements of Income (in thousands, except per share amounts) (unaudited) Three months Twelve months ended December 31, ended December 31, 2024 2023 2024 2023 Net revenues $4,113,722 $3,703,546 $15,827,935 $14,281,976 Operating charges:    Salaries, wages and benefits 1,907,383 1,799,008 7,518,687 7,107,484    Other operating expenses 1,142,901 998,732 4,308,384 3,757,216    Supplies expense 405,900 393,878 1,587,786 1,532,828    Depreciation and amortization 146,781 145,481 584,831 568,041    Lease and rental expense 38,268 35,251 146,433 141,026 3,641,233 3,372,350 14,146,121 13,106,595 Income from operations 472,489 331,196 1,681,814 1,175,381 Interest expense, net 39,724 53,589 186,109 206,674 Other (income) expense, net (5,546) (3,516) (2,231) 28,281 Income before income taxes 438,311 281,123 1,497,936 940,426 Provision for income taxes 101,264 61,501 334,827 221,119 Net income 337,047 219,622 1,163,109 719,307 Less:  Net income (loss) attributable to noncontrolling interests ("NCI") 4,650 3,244 21,012 1,512 Net income attributable to UHS $332,397 $216,378 $1,142,097 $717,795 Basic earnings per share attributable to UHS (a) $5.07 $3.19 $17.16 $10.35 Diluted earnings per share attributable to UHS (a) $4.96 $3.16 $16.82 $10.23 Universal Health Services, Inc. Footnotes to Consolidated Statements of Income (in thousands, except per share amounts) (unaudited) Three months Twelve months (a) Earnings per share calculation: ended December 31, ended December 31, 2024 2023 2024 2023 Basic and diluted: Net income attributable to UHS $332,397 $216,378 $1,142,097 $717,795 Less: Net income attributable to unvested restricted share grants 0 (66) (50) (308) Net income attributable to UHS - basic and diluted $332,397 $216,312 $1,142,047 $717,487 Weighted average number of common shares - basic 65,597 67,809 66,554 69,321 Basic earnings per share attributable to UHS: $5.07 $3.19 $17.16 $10.35 Weighted average number of common shares 65,597 67,809 66,554 69,321 Add: Other share equivalents 1,477 741 1,342 804 Weighted average number of common shares and equiv. - diluted 67,074 68,550 67,896 70,125 Diluted earnings per share attributable to UHS: $4.96 $3.16 $16.82 $10.23 Universal Health Services, Inc. Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule") For the Three Months ended December 31, 2024 and 2023 (in thousands, except per share amounts) (unaudited) Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI") Three months ended % Net Three months ended % Net December 31, 2024 revenues December 31, 2023 revenues Net income attributable to UHS $332,397 $216,378    Depreciation and amortization 146,781 145,481    Interest expense, net 39,724 53,589    Provision for income taxes 101,264 61,501 EBITDA net of NCI $620,166 15.1 % $476,949 12.9 % Other (income) expense, net (5,546) (3,516) Adjusted EBITDA net of NCI $614,620 14.9 % $473,433 12.8 % Net revenues $4,113,722 $3,703,546 Calculation of Adjusted Net Income Attributable to UHS Three months ended Three months ended December 31, 2024 December 31, 2023 Per Per Amount Diluted Share Amount Diluted Share Net income attributable to UHS $332,397 $4.96 $216,378 $3.16 Plus/minus after-tax adjustments: Unrealized gain on equity securities (2,053) (0.03) (1,470) (0.03) Impact of ASU 2016-09, net (407) (0.01) - - Subtotal adjustments (2,460) (0.04) (1,470) (0.03) Adjusted net income attributable to UHS $329,937 $4.92 $214,908 $3.13 Universal Health Services, Inc. Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule") For the Twelve Months ended December 31, 2024 and 2023 (in thousands, except per share amounts) (unaudited) Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI") Twelve months ended % Net Twelve months ended % Net December 31, 2024 revenues December 31, 2023 revenues Net income attributable to UHS $1,142,097 $717,795    Depreciation and amortization 584,831 568,041    Interest expense, net 186,109 206,674    Provision for income taxes 334,827 221,119 EBITDA net of NCI $2,247,864 14.2 % $1,713,629 12.0 % Other (income) expense, net (2,231) 28,281 Adjusted EBITDA net of NCI $2,245,633 14.2 % $1,741,910 12.2 % Net revenues $15,827,935 $14,281,976 Calculation of Adjusted Net Income Attributable to UHS Twelve months ended Twelve months ended December 31, 2024 December 31, 2023 Per Per Amount Diluted Share Amount Diluted Share Net income attributable to UHS $1,142,097 $16.82 $717,795 $10.23 Plus/minus after-tax adjustments: Unrealized loss on equity securities 1,985 0.03 21,570 0.31 Impact of ASU 2016-09, net (15,947) (0.24) - - Subtotal adjustments (13,962) (0.21) 21,570 0.31 Adjusted net income attributable to UHS $1,128,135 $16.61 $739,365 $10.54 Universal Health Services, Inc. Condensed Consolidated Balance Sheets (in thousands) (unaudited) December 31, December 31, 2024 2023 Assets Current assets:     Cash and cash equivalents $ 125,983 $ 119,439     Accounts receivable, net 2,177,751 2,238,265     Supplies 220,940 216,988     Other current assets 291,614 236,658           Total current assets 2,816,288 2,811,350 Property and equipment 12,643,283 11,777,047 Less: accumulated depreciation (6,071,058) (5,652,518) 6,572,225 6,124,529 Other assets:     Goodwill 3,932,879 3,932,407     Deferred income taxes 118,449 85,626     Right of use assets-operating leases 418,719 433,962     Deferred charges 9,404 6,974     Other 601,785 572,754 Total Assets $ 14,469,749 $ 13,967,602 Liabilities and Stockholders' Equity Current liabilities:     Current maturities of long-term debt $ 40,059 $ 126,686     Accounts payable and other liabilities 2,081,479 1,813,015     Operating lease liabilities 74,649 71,600     Federal and state taxes 14,219 2,046           Total current liabilities 2,210,406 2,013,347 Other noncurrent liabilities 655,806 584,007 Operating lease liabilities noncurrent 376,239 382,559 Long-term debt 4,464,482 4,785,783 Redeemable noncontrolling interest 13,293 5,191 UHS common stockholders' equity 6,666,207 6,149,001 Noncontrolling interest 83,316 47,714           Total equity 6,749,523 6,196,715 Total Liabilities and Stockholders' Equity $ 14,469,749 $ 13,967,602 Universal Health Services, Inc. Consolidated Statements of Cash Flows (in thousands) (unaudited) Twelve months ended December 31, 2024 2023 Cash Flows from Operating Activities:   Net income $1,163,109 $719,307   Adjustments to reconcile net income to net  cash provided by operating activities: Depreciation & amortization 584,831 568,041 Gains on sales of assets and businesses (9,920) (6,250) Stock-based compensation expense 99,349 87,720 Costs related to extinguishment of debt 3,158 0   Changes in assets & liabilities, net of effects from acquisitions and dispositions:    Accounts receivable 67,355 (182,444)    Accrued interest 12,814 1,193    Accrued and deferred income taxes  12,651 (43,450)    Other working capital accounts  61,897 (32,321)    Deferred grant revenue 0 2,978    Other assets and deferred charges (12,163) 48,517    Other  21,811 39,133    Accrued insurance expense, net of commercial premiums paid 254,394 183,462    Payments made in settlement of self-insurance claims (192,185) (118,089)           Net cash provided by operating activities 2,067,101 1,267,797 Cash Flows from Investing Activities:    Property and equipment additions (943,810) (743,055)    Acquisition of businesses and property (18,998) (3,728)    Inflows (outflows) from foreign exchange contracts that hedge our net U.K. investment 12,860 (40,695)    Proceeds received from sales of assets and businesses 38,563 24,187    Decrease in capital reserves of commercial insurance subsidiary  276 16           Net cash used in investing activities (911,109) (763,275) Cash Flows from Financing Activities:    Repayments of long-term debt (2,640,001) (85,480)    Additional borrowings 2,210,248 185,100    Financing costs (12,566) (308)    Repurchase of common shares (670,754) (547,363)    Dividends paid (53,346) (55,480)    Issuance of common stock 15,070 13,654    Profit distributions to noncontrolling interests (6,508) (6,830)    Sale of ownership interests to minority members 12,980 2,762           Net cash used in financing activities (1,144,877) (493,945)    Effect of exchange rate changes on cash, cash equivalents and restricted cash (833) 3,056 Increase in cash, cash equivalents and restricted cash 10,282 13,633 Cash, cash equivalents and restricted cash, beginning of period 214,470 200,837 Cash, cash equivalents and restricted cash, end of period $224,752 $214,470 Supplemental Disclosures of Cash Flow Information:   Interest paid $168,274 $200,446   Income taxes paid, net of refunds $325,430 $257,896   Noncash purchases of property and equipment $118,109 $66,899 Universal Health Services, Inc. Supplemental Statistical Information (unaudited)  % Change   % Change  3 Months ended 12 Months ended Same Facility: 12/31/2024 12/31/2024 Acute Care Hospitals Revenues 8.7 % 8.5 % Adjusted Admissions 2.2 % 2.9 % Adjusted Patient Days 0.1 % 1.8 % Revenue Per Adjusted Admission 5.3 % 5.1 % Revenue Per Adjusted Patient Day 7.5 % 6.3 % Behavioral Health Hospitals Revenues 11.1 % 10.7 % Adjusted Admissions 2.0 % 0.7 % Adjusted Patient Days 1.6 % 1.7 % Revenue Per Adjusted Admission 8.7 % 9.8 % Revenue Per Adjusted Patient Day 9.1 % 8.8 % UHS Consolidated Fourth Quarter Ended Twelve Months Ended 12/31/2024 12/31/2023 12/31/2024 12/31/2023 Revenues $4,113,722 $3,703,546 $15,827,935 $14,281,976 EBITDA net of NCI $620,166 $476,949 $2,247,864 $1,713,629 EBITDA Margin net of NCI 15.1 % 12.9 % 14.2 % 12.0 % Adjusted EBITDA net of NCI $614,620 $473,433 $2,245,633 $1,741,910 Adjusted EBITDA Margin net of NCI 14.9 % 12.8 % 14.2 % 12.2 % Cash Flow From Operations $658,437 $452,431 $2,067,101 $1,267,797 Capital Expenditures   $245,945 $206,390 $943,810 $743,055 Days Sales Outstanding 50 57 Debt  $4,504,541 $4,912,469 UHS' Shareholders Equity $6,666,207 $6,149,001 Debt / Total Capitalization 40.3 % 44.4 % Debt / EBITDA net of NCI (1) 2.00 2.87 Debt / Adjusted EBITDA net of NCI (1) 2.01 2.82 Debt / Cash From Operations (1) 2.18 3.87 Universal Health Services, Inc. Acute Care Hospital Services For the Three and Twelve months ended December 31, 2024 and 2023 (in thousands) (unaudited) Same Facility Basis - Acute Care Hospital Services Three months ended Three months ended Twelve months ended Twelve months ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Amount % of NetRevenues  Amount % of NetRevenues  Amount % of NetRevenues  Amount % of NetRevenues  Net revenues $2,210,767 100.0 % $2,034,152 100.0 % $8,565,845 100.0 % $7,892,167 100.0 % Operating charges: Salaries, wages and benefits 893,101 40.4 % 870,680 42.8 % 3,502,645 40.9 % 3,387,843 42.9 % Other operating expenses 623,513 28.2 % 559,985 27.5 % 2,378,512 27.8 % 2,164,069 27.4 % Supplies expense 347,034 15.7 % 338,815 16.7 % 1,358,636 15.9 % 1,315,527 16.7 % Depreciation and amortization 86,845 3.9 % 93,421 4.6 % 364,907 4.3 % 367,067 4.7 % Lease and rental expense 26,422 1.2 % 23,970 1.2 % 98,730 1.2 % 96,429 1.2 % Subtotal-operating expenses 1,976,915 89.4 % 1,886,871 92.8 % 7,703,430 89.9 % 7,330,935 92.9 % Income from operations 233,852 10.6 % 147,281 7.2 % 862,415 10.1 % 561,232 7.1 % Interest expense, net  2,976 0.1 % (643) (0.0) % 6,339 0.1 % (2,501) (0.0) % Other (income) expense, net  (775) (0.0) % 1,277 0.1 % (2,123) (0.0) % 7,000 0.1 % Income before income taxes $231,651 10.5 % $146,647 7.2 % $858,199 10.0 % $556,733 7.1 % All Acute Care Hospital Services Three months ended Three months ended Twelve months ended Twelve months ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Amount % of NetRevenues Amount % of NetRevenues  Amount % of NetRevenues Amount % of NetRevenues  Net revenues $2,318,320 100.0 % $2,087,503 100.0 % $8,922,327 100.0 % $8,081,402 100.0 % Operating charges: Salaries, wages and benefits 899,241 38.8 % 871,182 41.7 % 3,511,359 39.4 % 3,406,060 42.1 % Other operating expenses 734,189 31.7 % 615,810 29.5 % 2,743,420 30.7 % 2,347,560 29.0 % Supplies expense 348,551 15.0 % 338,732 16.2 % 1,360,011 15.2 % 1,317,917 16.3 % Depreciation and amortization 89,048 3.8 % 93,479 4.5 % 368,096 4.1 % 367,644 4.5 % Lease and rental expense 26,422 1.1 % 23,960 1.1 % 99,060 1.1 % 96,589 1.2 % Subtotal-operating expenses 2,097,451 90.5 % 1,943,163 93.1 % 8,081,946 90.6 % 7,535,770 93.2 % Income from operations 220,869 9.5 % 144,340 6.9 % 840,381 9.4 % 545,632 6.8 % Interest expense, net  2,976 0.1 % (643) (0.0) % 6,339 0.1 % (2,501) (0.0) % Other (income) expense, net  (951) (0.0) % 867 0.0 % (1,305) (0.0) % 7,788 0.1 % Income before income taxes $218,844 9.4 % $144,116 6.9 % $835,347 9.4 % $540,345 6.7 % We believe that providing our results on a "Same Facility" basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2024. The All Acute Care Hospital Services table summarizes the results of operations for all our acute care operations during the periods presented. These amounts include: (i) our acute care results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months. Universal Health Services, Inc. Behavioral Health Care Services For the Three and Twelve months ended December 31, 2024 and 2023 (in thousands) (unaudited) Same Facility - Behavioral Health Care Services Three months ended Three months ended Twelve months ended Twelve months ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Amount % of NetRevenues  Amount % of NetRevenues  Amount % of NetRevenues  Amount % of NetRevenues  Net revenues $1,727,857 100.0 % $1,555,700 100.0 % $6,700,469 100.0 % $6,050,491 100.0 % Operating charges: Salaries, wages and benefits 911,047 52.7 % 851,507 54.7 % 3,590,985 53.6 % 3,346,357 55.3 % Other operating expenses 328,339 19.0 % 299,035 19.2 % 1,262,446 18.8 % 1,168,806 19.3 % Supplies expense 58,201 3.4 % 55,509 3.6 % 229,795 3.4 % 216,880 3.6 % Depreciation and amortization 55,050 3.2 % 48,879 3.1 % 204,144 3.0 % 188,237 3.1 % Lease and rental expense 11,560 0.7 % 11,135 0.7 % 46,468 0.7 % 43,819 0.7 % Subtotal-operating expenses 1,364,197 79.0 % 1,266,065 81.4 % 5,333,838 79.6 % 4,964,099 82.0 % Income from operations 363,660 21.0 % 289,635 18.6 % 1,366,631 20.4 % 1,086,392 18.0 % Interest expense, net  951 0.1 % 1,102 0.1 % 4,027 0.1 % 4,557 0.1 % Other (income) expense, net  (1,139) (0.1) % (1,132) (0.1) % (3,480) (0.1) % (3,426) (0.1) % Income before income taxes $363,848 21.1 % $289,665 18.6 % $1,366,084 20.4 % $1,085,261 17.9 % All Behavioral Health Care Services Three months ended Three months ended Twelve months ended Twelve months ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Amount % of NetRevenues Amount % of NetRevenues  Amount % of NetRevenues Amount % of NetRevenues  Net revenues $1,792,761 100.0 % $1,615,543 100.0 % $6,895,051 100.0 % $6,190,921 100.0 % Operating charges: Salaries, wages and benefits 913,005 50.9 % 854,670 52.9 % 3,603,123 52.3 % 3,353,008 54.2 % Other operating expenses 393,496 21.9 % 353,353 21.9 % 1,447,503 21.0 % 1,303,311 21.1 % Supplies expense 58,243 3.2 % 55,713 3.4 % 230,274 3.3 % 217,310 3.5 % Depreciation and amortization 55,413 3.1 % 49,180 3.0 % 206,362 3.0 % 189,297 3.1 % Lease and rental expense 11,751 0.7 % 11,194 0.7 % 46,986 0.7 % 44,028 0.7 % Subtotal-operating expenses 1,431,908 79.9 % 1,324,110 82.0 % 5,534,248 80.3 % 5,106,954 82.5 % Income from operations 360,853 20.1 % 291,433 18.0 % 1,360,803 19.7 % 1,083,967 17.5 % Interest expense, net  951 0.1 % 1,102 0.1 % 4,027 0.1 % 4,558 0.1 % Other (income) expense, net  (1,139) (0.1) % (1,132) (0.1) % (3,547) (0.1) % (4,271) (0.1) % Income before income taxes $361,041 20.1 % $291,463 18.0 % $1,360,323 19.7 % $1,083,680 17.5 % We believe that providing our results on a "Same Facility" basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Behavioral Health Care Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2024. The All Behavioral Health Care Services table summarizes the results of operations for all our behavioral health care facilities during the periods presented. These amounts include: (i) our behavioral health results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months. Universal Health Services, Inc. Selected Hospital Statistics For the Three Months ended December 31, 2024 and 2023 (unaudited) AS REPORTED: ACUTE BEHAVIORAL HEALTH 12/31/24 12/31/23 %  change 12/31/24 12/31/23 %  change Hospitals owned and leased 28 27 3.7 % 331 333 -0.6 % Average licensed beds 6,707 6,674 0.5 % 24,220 24,285 -0.3 % Average available beds 6,535 6,502 0.5 % 24,120 24,185 -0.3 % Patient days 402,288 403,117 -0.2 % 1,588,205 1,575,040 0.8 % Average daily census 4,372.7 4,381.7 -0.2 % 17,263.1 17,120.0 0.8 % Occupancy-licensed beds 65.2 % 65.7 % -0.7 % 71.3 % 70.5 % 1.1 % Occupancy-available beds 66.9 % 67.4 % -0.7 % 71.6 % 70.8 % 1.1 % Admissions 84,245 82,918 1.6 % 115,435 113,604 1.6 % Length of stay 4.8 4.9 -1.8 % 13.8 13.9 -0.8 % Inpatient revenue $12,488,383 $11,408,639 9.5 % $2,754,078 $2,647,158 4.0 % Outpatient revenue 8,645,327 7,566,625 14.3 % 285,076 275,128 3.6 % Total patient revenue 21,133,710 18,975,264 11.4 % 3,039,154 2,922,286 4.0 % Other revenue 251,226 234,117 7.3 % 83,795 83,153 0.8 % Gross revenue 21,384,936 19,209,381 11.3 % 3,122,949 3,005,439 3.9 % Total deductions 19,066,616 17,121,878 11.4 % 1,330,188 1,389,896 -4.3 % Net revenue  $2,318,320 $2,087,503 11.1 % $1,792,761 $1,615,543 11.0 % SAME FACILITY: ACUTE BEHAVIORAL HEALTH 12/31/24 12/31/23 %  change 12/31/24 12/31/23 %  change Hospitals owned and leased 27 27 0.0 % 330 330 0.0 % Average licensed beds 6,657 6,674 -0.3 % 24,094 23,821 1.1 % Average available beds 6,485 6,502 -0.3 % 23,994 23,721 1.2 % Patient days 401,166 403,107 -0.5 % 1,578,242 1,550,485 1.8 % Average daily census 4,360.5 4,381.6 -0.5 % 17,154.8 16,853.1 1.8 % Occupancy-licensed beds 65.5 % 65.7 % -0.2 % 71.2 % 70.7 % 0.6 % Occupancy-available beds 67.2 % 67.4 % -0.2 % 71.5 % 71.0 % 0.6 % Admissions 83,943 82,918 1.2 % 114,684 112,232 2.2 % Length of stay 4.8 4.9 -1.7 % 13.8 13.8 -0.4 % Universal Health Services, Inc. Selected Hospital Statistics For the Twelve Months ended December 31, 2024 and 2023 (unaudited) AS REPORTED: ACUTE BEHAVIORAL HEALTH 12/31/24 12/31/23 %  change 12/31/24 12/31/23 %  change Hospitals owned and leased 28 27 3.7 % 331 333 -0.6 % Average licensed beds 6,670 6,691 -0.3 % 24,367 24,224 0.6 % Average available beds 6,498 6,519 -0.3 % 24,280 24,124 0.6 % Patient days 1,601,579 1,576,074 1.6 % 6,446,651 6,336,927 1.7 % Average daily census 4,375.9 4,318.0 1.3 % 17,613.8 17,361.4 1.5 % Occupancy-licensed beds 65.6 % 64.5 % 1.7 % 72.3 % 71.7 % 0.9 % Occupancy-available beds 67.3 % 66.2 % 1.7 % 72.5 % 72.0 % 0.8 % Admissions 331,415 322,218 2.9 % 476,584 472,307 0.9 % Length of stay 4.8 4.9 -1.9 % 13.5 13.4 0.6 % Inpatient revenue $50,010,778 $44,687,035 11.9 % $11,129,548 $10,648,996 4.5 % Outpatient revenue 34,198,778 29,858,874 14.5 % 1,118,336 1,087,595 2.8 % Total patient revenue 84,209,556 74,545,909 13.0 % 12,247,884 11,736,591 4.4 % Other revenue 998,650 948,994 5.2 % 330,977 303,546 9.0 % Gross revenue 85,208,206 75,494,903 12.9 % 12,578,861 12,040,137 4.5 % Total deductions 76,285,879 67,413,501 13.2 % 5,683,810 5,849,216 -2.8 % Net revenue  $8,922,327 $8,081,402 10.4 % $6,895,051 $6,190,921 11.4 % SAME FACILITY: ACUTE BEHAVIORAL HEALTH 12/31/24 12/31/23 %  change 12/31/24 12/31/23 %  change Hospitals owned and leased 27 27 0.0 % 330 330 0.0 % Average licensed beds 6,657 6,644 0.2 % 24,165 24,000 0.7 % Average available beds 6,485 6,472 0.2 % 24,065 23,900 0.7 % Patient days 1,600,445 1,569,792 2.0 % 6,397,790 6,277,015 1.9 % Average daily census 4,372.8 4,300.8 1.7 % 17,480.3 17,197.3 1.6 % Occupancy-licensed beds 65.7 % 64.7 % 1.5 % 72.3 % 71.7 % 1.0 % Occupancy-available beds 67.4 % 66.5 % 1.5 % 72.6 % 72.0 % 0.9 % Admissions 331,113 321,155 3.1 % 472,798 468,260 1.0 % Length of stay 4.8 4.9 -2.0 % 13.5 13.4 0.7 % Universal Health Services, Inc. Supplemental Non-GAAP Disclosures 2025 Operating Results Forecast (in thousands, except per share amounts) Forecast For The Year Ending December 31, 2025 % Net % Net Low revenues High revenues Net revenues $17,020,000 $17,364,000 Net income attributable to UHS (a) $1,199,798 $1,297,005  Depreciation and amortization 639,574 639,574  Interest expense 150,253 150,253  Other (income) expense, net (9,902) (9,902)  Provision for income taxes 376,809 407,338 Adjusted EBITDA net of NCI (b) $2,356,532 13.8 % $2,484,268 14.3 % Net income attributable to UHS, per diluted share (a) $18.45 $19.95 Shares used in computing diluted earnings per share 65,017 65,017 (a) Forecasted net income attributable to UHS/per diluted share exclude the following items because we do not believe we can forecast these items with sufficient accuracy. Such items include: the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as pre-tax unrealized gains/losses resulting from changes in the market value of shares of certain equity securities, the impact of ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m), and other potential material items including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary acquisitions, divestitures, joint ventures or other strategic transactions, other amounts that may be reflected in the current or prior year financial statements that relate to prior periods, and the impact of share repurchases that differ from our forecasted assumptions. Forecasted net income attributable to UHS/per diluted share is also subject to certain conditions including those as set forth in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures. (b) Adjusted EBITDA net of NCI is a non-GAAP financial measure and should not be considered a measure of financial performance under GAAP.  We believe Adjusted EBITDA net of NCI is helpful to our investors as a measure of operating performance. SOURCE Universal Health Services, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News